Pages that link to "Q33819486"
Jump to navigation
Jump to search
The following pages link to Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration (Q33819486):
Displaying 50 items.
- Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial (Q22242637) (← links)
- BBS-induced ciliary defect enhances adipogenesis, causing paradoxical higher-insulin sensitivity, glucose usage, and decreased inflammatory response (Q24298309) (← links)
- Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review (Q24561401) (← links)
- Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial (Q24645513) (← links)
- Cardiovascular safety of anti-diabetic drugs (Q26741082) (← links)
- Pancreatic regulation of glucose homeostasis (Q26766485) (← links)
- Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma (Q28366616) (← links)
- First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents (Q33845881) (← links)
- Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas (Q33867088) (← links)
- Drug-induced liver disease (Q34057571) (← links)
- Disorders of glucose metabolism in patients infected with human immunodeficiency virus (Q34092346) (← links)
- Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review (Q34100675) (← links)
- Pharmacogenomics: will it change the field of medicine? (Q34285979) (← links)
- Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse. (Q34294773) (← links)
- Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. (Q34315432) (← links)
- Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). (Q34347608) (← links)
- Ongoing challenges in pharmacovigilance (Q34417013) (← links)
- Hepatotoxicity with thiazolidinediones: is it a class effect? (Q34458520) (← links)
- Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes (Q34469377) (← links)
- Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure (Q34502676) (← links)
- Hepatotoxicity of thiazolidinediones (Q34570521) (← links)
- Are all glitazones the same? (Q34580975) (← links)
- Mechanisms of disease:Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes (Q34737010) (← links)
- Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases (Q34992771) (← links)
- The liver in obesity and type 2 diabetes mellitus (Q35040091) (← links)
- Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence (Q35162317) (← links)
- Hepatotoxicity of the thiazolidinediones (Q35184558) (← links)
- Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats (Q35218115) (← links)
- Non-alcoholic fatty liver: a common manifestation of a metabolic disorder (Q35538766) (← links)
- Troglitazone and liver injury: in search of answers (Q36013357) (← links)
- Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells (Q36067499) (← links)
- Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer (Q36187022) (← links)
- PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy (Q36200396) (← links)
- Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones (Q36305927) (← links)
- Mechanisms of drug-induced liver injury. (Q36439183) (← links)
- Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes (Q36871062) (← links)
- Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats (Q36943606) (← links)
- PPARgamma, PTEN, and the Fight against Cancer (Q37014943) (← links)
- Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update (Q37142138) (← links)
- Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment (Q37149405) (← links)
- Identification of PPARγ ligands with One-dimensional Drug Profile Matching (Q37165170) (← links)
- Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache (Q37267783) (← links)
- Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models (Q37391731) (← links)
- Important elements for the diagnosis of drug-induced liver injury (Q37512625) (← links)
- Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. (Q37564187) (← links)
- The safety of thiazolidinediones (Q37848841) (← links)
- The Current Knowledge of the Role of PPAR in Hepatic Ischemia-Reperfusion Injury. (Q38016858) (← links)
- Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics (Q38151571) (← links)
- Endoplasmic reticulum stress in drug- and environmental toxicant-induced liver toxicity (Q38193602) (← links)
- Effect of Thiazolidinediones on the Erythropoeitic and Germinal Cells in the Male Wistar Rats (Q38260621) (← links)